Jim, re. table with brief descriptions of CD antigens:
Try this: rncc.bidmc.harvard.edu
or this for even more recent information:
ncbi.nlm.nih.gov
The anti-CD40-Ligand (or should I say anti-CD154? -g-) approach is quite exciting. I think the Kirk reference is key, here it is just in case:
Proc Natl Acad Sci U S A 1997 Aug 5;94(16):8789-94
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ
ncbi.nlm.nih.gov
I am not aware of data as strong as the above for anti-CD2. However, Rick does have special insight here, and I am curious to see his take.
Both Biogen and IDEC are developing humanized antibodies against CD40L; interestingly IDEC has also began testing of a primatized MAb against B7 (not clear if B7.1 or B7.2) for psoriasis. None of these trials are in transplantation to my knowledge.
Hope this helps some, and let's see what Rick has up his sleeve.
Happy thanksgiving to you too,
PB |
